Coronary/Structural Heart

FEops Simulation Technology Supports TRiCares From Initial Design Concepts to a Successful First-in-human

GENT, Belgium–(BUSINESS WIRE)–FEops, a leader in predictive planning for structural heart interventions, is proud to announce that its simulation technology supported TRiCares from initial design concept to a successful first-in-human of the Topaz Tricuspid Valve Replacement (TTVR) system, developed by TRiCares SAS. This is a major step forward towards predictive […]

PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focus shifting to enrollment of patients with uncontrolled major or life-threatening bleeding Phase […]

Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL® (cangrelor) in Cardiac Patients at High Risk of Complications Following PCI in the American Journal of Cardiovascular Drugs

CARY, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) — Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the publication of a cost-consequence analysis of KENGREAL® (cangrelor) in patients receiving percutaneous coronary intervention (PCI) in the online edition of the American Journal of Cardiovascular Drugs. KENGREAL […]

PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab

Enrollment in the REVERSE-IT global Phase 3 trial from clinical sites in China expected to begin later in 2021 MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Investigational New […]

Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

− Full Study Enrollment Completed Well Ahead of Schedule − CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients […]

BioStable Science & Engineering Initiates European Commercialization of the HAART™ 200 Aortic Annuloplasty Device

First commercial implantations of the HAART 200 Device for Bicuspid Aortic Valve repair performed by Professor Marek Jasinski at the Wroclaw Medical University AUSTIN, Texas–(BUSINESS WIRE)–BioStable Science & Engineering, Inc. announced today that the first commercial implantations of its HAART 200 Aortic Annuloplasty Device were performed on Monday, August 2nd by Professor […]

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/dJwHD Controlling […]

Columbia Asia Referral Hospitals (A Unit of Manipal Hospitals) demonstrates ‘Door-to-Balloon’ procedure, launches new Cath Lab at Yeshwanthpur Unit

BANGALORE, India, Aug. 6, 2021 /PRNewswire/ — Columbia Asia Referral Hospitals Yeshwanthpur (A Unit of Manipal Hospitals), today announced the launch of a new Cath Lab unit to highlight and demonstrate the importance of ‘Door-to-Balloon’ time during cardiac emergencies. Anand Hedge (name changed), a 56-year-old gentleman was working at his factory when he suffered a […]

Abcentra Announces First Patients Dosed with Orticumab in Clinical Trial Evaluating Blockade of Oxidized LDL in Psoriasis with Elevated Cardiometabolic Risk

LOS ANGELES, Aug. 4, 2021 /PRNewswire/ — Today, Abcentra LLC announced that the first patients have been dosed in its multi-center phase 2 trial assessing the safety and activity of orticumab in patients with moderate-to-severe plaque psoriasis and cardiometabolic risk factors. Orticumab is a fully-human monoclonal antibody against a specific oxidized low-density lipoprotein (LDL) epitope. Seventeen […]

Clinical Trial Shows Injectable Weight Loss Drug Directly Reduces Abdominal Fat

Findings could potentially widen use for overweight adults who are high risk for heart disease   CLEVELAND – A clinical trial led by Dr. Ian Neeland with University Hospitals Harrington Heart & Vascular Institute could have implications for overweight and obese adults who may benefit from reducing intra-abdominal fat. The […]